"Theranostic Nanomedicine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An integrated nano-scale approach to MEDICINE which involves concurrent diagnosis, drug delivery, therapy, and monitoring of therapeutic response.
| Descriptor ID |
D000068936
|
| MeSH Number(s) |
E01.894 E02.921 H01.603.600.500 H02.403.845 J01.897.520.600.600.500
|
| Concept/Terms |
Theranostic Nanomedicine- Theranostic Nanomedicine
- Nanomedicine, Theranostic
- Nanomedicines, Theranostic
- Theranostic Nanomedicines
|
Below are MeSH descriptors whose meaning is more general than "Theranostic Nanomedicine".
Below are MeSH descriptors whose meaning is more specific than "Theranostic Nanomedicine".
This graph shows the total number of publications written about "Theranostic Nanomedicine" by people in this website by year, and whether "Theranostic Nanomedicine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Theranostic Nanomedicine" by people in Profiles.
-
Potential of Technetium and Rhenium Theranostics. Semin Nucl Med. 2025 Sep; 55(5):829-840.
-
Sharpening the Blade of Precision Theranostics. Semin Nucl Med. 2025 Sep; 55(5):841-855.
-
The developing role of theranostics in NETs. Lancet. 2024 06 29; 403(10446):2759-2761.
-
Nanotechnology synergized immunoengineering for cancer. Eur J Pharm Biopharm. 2021 Jun; 163:72-101.
-
Stimuli-Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy. Adv Healthc Mater. 2021 03; 10(5):e2001044.
-
Roadmap for metal nanoparticles in radiation therapy: current status, translational challenges, and future directions. Phys Med Biol. 2020 10 22; 65(21):21RM02.
-
RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 2020; 10(18):7974-7992.
-
Liposomal nanotheranostics for multimode targeted in vivo bioimaging and near-infrared light mediated cancer therapy. Commun Biol. 2020 06 05; 3(1):284.
-
Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 09; 12(5):e1628.
-
Bypassing pro-survival and resistance mechanisms of autophagy in EGFR-positive lung cancer cells by targeted delivery of 5FU using theranostic Ag2S quantum dots. J Mater Chem B. 2019 12 14; 7(46):7363-7376.